Novo Nordisk A (NVO) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novo Nordisk A  (NYSE: NVO)


Novo Nordisk A's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Novo Nordisk A's ROI in the first quarter of 2026?
Novo Nordisk A achieved a return on average invested assets (ROI) of 25.62 % in its first quarter of 2026, which is below Novo Nordisk A's average return on investment, which stands at 35.69%.

ROI has improved compared to 23.47% in the fourth quarter of 2025, due to net income growth.

Within the Healthcare sector 52 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 203, from total ROI ranking in the fourth quarter of 2025 at 209.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 4.6 % -4.09 % 80.49 % 88.6 % 91.2 %
Y / Y Net Income Change TTM 26.42 % 5.93 % 44.13 % 145.51 % 306.83 %
Investment (TTM) in Millions 83,935 64,672 76,779 71,615 51,421
Return On Investment (TTM) 25.62 % 23.47 % 19.13 % 21.4 % 21.2 %
NVO's Overall Ranking # 203 # 209 # # #
Seq. Investment Change TTM 12.29 % -17.31 % 5.74 % 6.54 % 2.96 %
Seq. Net Income Change TTM 22.6 % 1.45 % -5.49 % 7.54 % 2.73 %
Net Income (TTM) in Millions 19,025 15,518 15,296 16,184 15,049

NVO Company Profile >> Back to NVO Roi Comparisons >> See Annual NVO Return On Investment



Return On Investment NVO's Ranking
Within: No.
Industry # 26
Sector # 53
Overall # 203

Return On Investment Statistics
High Average Low
70.52 %
35.69 %
14.32 %
(Dec 31 2018)   (Dec 31 2022)







Financial Statements
Novo Nordisk A's I. Quarter Investments $ 83,935 Millions NVO's Balance sheet
Novo Nordisk A's I. Quarter Income $ 7,606 Millions Quarterly NVO's Income Statement
NVO's Income by Division See NVO's Income by Division


NVO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 158,113 120,036 21,520 17,323 14,512
Y / Y Investment Growth 31.72 % 457.79 % 24.23 % 19.37 % 18.28 %
Net Income in Millions 15,518 14,649 12,148 7,861 7,597
Y / Y Net Income Growth 5.93 % 20.59 % 54.53 % 3.48 % 17.78 %
Annual Return On Investment 9.81 % 12.2 % 56.45 % 45.38 % 52.35 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 9.81 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NVO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NVO's Competitors
Subscribers only: Roi for Novo Nordisk A's Suppliers
Subscribers only: Return On Investment for NVO's Customers

Other Ratios
NVO's Roa NVO's Inventory Turnover Ratio NVO's Growth Rates NVO's Dividend Statistics
NVO's Profitability Ratios NVO's Asset Turnover Ratio NVO's Dividend Growth
NVO's Roe NVO's Valuation Ratios NVO's Financial Strength Ratios NVO's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Earth Science Tech Inc   68.75 %
Q32 Bio Inc   58.17 %
Oramed Pharmaceuticals Inc  54.33 %
Aurinia Pharmaceuticals Inc   54.02 %
Vaxart Inc   51.45 %
Escalon Medical Corp   51.07 %
Tg Therapeutics Inc   50.62 %
Zevra Therapeutics Inc   50.45 %
Idexx Laboratories Inc  50.05 %
Theravance Biopharma inc   43.85 %
Elite Pharmaceuticals Inc   43.22 %
Dariohealth Corp   40.59 %
Innoviva Inc   36.71 %
Indivior Pharmaceuticals Inc   36.55 %
Eli Lilly And Company  36.13 %
Abeona Therapeutics Inc   35.03 %
Lifemd Inc   34.80 %
Acadia Pharmaceuticals Inc   34.03 %
Mettler toledo International Inc   33.62 %
Adma Biologics Inc   30.38 %
Medpace Holdings Inc   30.34 %
Spero Therapeutics Inc   29.59 %
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %

Date modified: 2026-09-30T13:42:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.